3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
10
Endocrine
2
NET
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
1
Neuroendocrine Prostate Cancer
1
Neoplasms
1
Interventions
lutetium Lu 177 dotatate
30
Magnetic Resonance Spectroscopy
25
pembrolizumab
21
Specimen Handling
18
Nivolumab
17
cabozantinib
14
lenvatinib
12
Everolimus
12
trametinib
11
gallium Ga 68 dotatate
10
dabrafenib
10
Ipilimumab
10
Carboplatin
10
Cisplatin
8
atezolizumab
7
Temozolomide
7
Lutetium-177
7
X-Rays
6
Etoposide
6
Capecitabine
6
surufatinib
5
lanreotide
5
fluorodopa F 18
5
cemiplimab
5
Vemurafenib
5
Paclitaxel
5
Octreotide
5
Lutetium
5
Fluorodeoxyglucose F18
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
AMG 757
×
Endocrine
×
1 year
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts
NCT04702737
2025-09-12
DeLLpro-300
Amgen
Phase 1
Completed
41 enrolled
19 charts